Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus gemcitabine/cisplatin and primary radiotherapy for newly diagnosed metastatic nasopharyngeal carcinoma
ChiCTR1900022683Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by West China Hospital of Sichuan University. Primary endpoint: overall survival. Planned start May 2019; status: not yet recruiting.
02
Drugs
sintilimabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1900022683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022683.